Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Bajaj

Showing results (71-80 of 75) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 75 results.
Archives of Internal Medicine|April 12, 2012
Use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and cardiovascular outcomes in chronic dialysis patients: a population-based cohort studyRavi R Bajaj, Ron Wald, Daniel G Hackam, et al.
The American Journal of Cardiology|November 6, 2012
Treatment and outcomes of patients with suspected acute coronary syndromes in relation to initial diagnostic impressions (insights from the Canadian Global Registry of Acute Coronary Events [GRACE] and Canadian Registry of Acute Coronary Events [CANRACE])Ravi R Bajaj, Shaun G Goodman, Raymond T Yan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 23, 2015
A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancerB H O'Neil, A J Scott, W W Ma, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 21, 2015
A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancerB H O'Neil, A J Scott, W W Ma, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 6, 2016
A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancerB H O'Neil, A J Scott, W W Ma, et al.
Pageof 8

Showing results (71-80 of 75) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 75 results.
Archives of Internal Medicine|April 12, 2012
Use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and cardiovascular outcomes in chronic dialysis patients: a population-based cohort studyRavi R Bajaj, Ron Wald, Daniel G Hackam, et al.
The American Journal of Cardiology|November 6, 2012
Treatment and outcomes of patients with suspected acute coronary syndromes in relation to initial diagnostic impressions (insights from the Canadian Global Registry of Acute Coronary Events [GRACE] and Canadian Registry of Acute Coronary Events [CANRACE])Ravi R Bajaj, Shaun G Goodman, Raymond T Yan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 23, 2015
A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancerB H O'Neil, A J Scott, W W Ma, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 21, 2015
A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancerB H O'Neil, A J Scott, W W Ma, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 6, 2016
A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancerB H O'Neil, A J Scott, W W Ma, et al.
Pageof 8